Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371979 · ClinicalTrials.gov registry record · Phase 1
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
A Phase 1 study, sponsored by Aeglea Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03371979 is a Phase 1 study that has completed, run by Aeglea Biotherapeutics. The registered enrollment target is 68 participants.
The verdict
NCT03371979, a Phase 1 study, has completed, sponsored by Aeglea Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Interventions
- DRUG Pembrolizumab
- DRUG Pegzilarginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371979
The ClinicalTrials.gov registry entry for NCT03371979 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aeglea Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03371979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03371979 about?
NCT03371979 is a clinical study titled "Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer". The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
What is the current status of trial NCT03371979?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2017-12-21. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT03371979?
The interventions under investigation include: Pembrolizumab (DRUG), Pegzilarginase (DRUG).
Who is sponsoring clinical trial NCT03371979?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.